We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-1.16%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.86B
AUM Growth
+$4.04B
Cap. Flow
+$4.05B
Cap. Flow %
69.18%
Top 10 Hldgs %
42.44%
Holding
220
New
83
Increased
86
Reduced
22
Closed
19

Top Buys

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$541M
2
INCY icon
Incyte
INCY
+$293M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$290M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$228M
5
SAGE
Sage Therapeutics
SAGE
+$223M

Top Sells

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$28.3M
2
COR icon
Cencora
COR
+$19.9M
3
PRAH
PRA Health Sciences, Inc.
PRAH
+$16.5M
4
WBA
Walgreens Boots Alliance
WBA
+$14.7M
5
ILMN icon
Illumina
ILMN
+$9.58M

Sector Composition

Rank Sector Weight
1 Healthcare 94.72%
2 Technology 0.56%
3 Industrials 0.42%
4 Financials 0.06%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZBH icon
76
Zimmer Biomet
ZBH
$17.6B
$11.9M 0.2%
104,235
-14,165
-12% -$1.66M
INSP icon
77
Inspire Medical Systems
INSP
$1.46B
$11.8M 0.2%
194,340
+71,235
+58% +$3.84M
MOH icon
78
Molina Healthcare
MOH
$11.7B
$11.7M 0.2%
81,661
+9,821
+14% +$1.35M
GMED icon
79
Globus Medical
GMED
$10.5B
$11.6M 0.2%
273,482
+34,972
+15% +$1.52M
ONC
80
BeOne Medicines Ltd
ONC
$32.4B
$11.5M 0.2%
93,000
-9,200
-9% -$1.17M
TNDM icon
81
Tandem Diabetes Care
TNDM
$1.17B
$10.8M 0.18%
167,847
+40,306
+32% +$2.6M
COO icon
82
Cooper Companies
COO
$14B
$10.8M 0.18%
127,876
+9,400
+8% +$707K
IART icon
83
Integra LifeSciences
IART
$1.5B
$10.7M 0.18%
191,733
-30,617
-14% -$1.58M
GH icon
84
Guardant Health
GH
$20.7B
$10.3M 0.18%
119,848
+10,196
+9% +$779K
XENT
85
DELISTED
Intersect ENT, Inc
XENT
$10.3M 0.18%
450,718
+122,331
+37% +$3.3M
PODD icon
86
Insulet
PODD
$11.4B
$9.94M 0.17%
83,246
+65,246
+362% +$6.69M
MASI
87
DELISTED
Masimo
MASI
$9.76M 0.17%
65,592
+42,812
+188% +$5.87M
TRHC
88
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
$9.54M 0.16%
191,175
+75,713
+66% +$3.77M
KZR
89
DELISTED
Kezar Life Sciences
KZR
$9.49M 0.16%
+123,052
New +$19.1M
NVRO
90
DELISTED
NEVRO CORP.
NVRO
$9.11M 0.16%
140,548
+12,146
+9% +$756K
IDXX icon
91
Idexx Laboratories
IDXX
$44.8B
$8.93M 0.15%
32,449
+5,047
+18% +$1.24M
AMGN icon
92
Amgen
AMGN
$198B
$8.59M 0.15%
46,600
+32,100
+221% +$5.75M
GKOS icon
93
Glaukos
GKOS
$9.21B
$8.09M 0.14%
+107,235
New +$7.69M
VEEV icon
94
Veeva Systems
VEEV
$31.7B
$8.04M 0.14%
49,590
-2,520
-5% -$367K
OXFD
95
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$7.96M 0.14%
578,615
+52,453
+10% +$802K
XRAY icon
96
Dentsply Sirona
XRAY
$2.81B
$7.31M 0.12%
125,313
+14,435
+13% +$776K
HOLX
97
DELISTED
Hologic
HOLX
$7.08M 0.12%
147,548
+57,548
+64% +$2.66M
BIIB icon
98
Biogen
BIIB
$30.4B
$6.91M 0.12%
29,550
+21,100
+250% +$4.87M
QTNT
99
DELISTED
Quotient Limited Ordinary Shares
QTNT
$6.86M 0.12%
18,336
-1,541
-8% -$550K
INGN icon
100
Inogen
INGN
$178M
$6.46M 0.11%
96,843
+27,116
+39% +$2.06M
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2019 Portfolio in Review

As of Q2 2019, Bellevue Group held 220 positions worth $5.86B, up 222% from $1.82B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Bellevue Group deployed $4.05B of net new capital in Q2 2019, opening 83 new positions and adding to 86 existing holdings. Its largest new stake was Agios Pharmaceuticals: 3,128,134 shares worth $156M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 91% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Wellcare Health Plans, Inc., an estimated $28.3M trimmed.

  • Bellevue Group's largest Q2 2019 buy was Agios Pharmaceuticals: 3,128,134 shares worth $156M.
  • Bellevue Group added most to Ionis Pharmaceuticals in Q2 2019, an estimated $541M increase.
  • Bellevue Group's biggest Q2 2019 reduction was Wellcare Health Plans, Inc., cutting an estimated $28.3M.
  • Bellevue Group fully exited Cencora in Q2 2019, selling an estimated $19.9M.
  • Bellevue Group's ten largest holdings make up 42% of its $5.86B portfolio in Q2 2019.
  • Bellevue Group opened 83 new positions and closed 19 in Q2 2019.
  • Bellevue Group's portfolio value rose 222% quarter-over-quarter to $5.86B.

Based on Bellevue Group's 13F filing for Q2 2019, filed 14 Aug 2019.